Table 1.
Characteristics of the included trials and participants
| Author | Year | Patients | Gender (M/F) | Mean age (year) | Sample | Events/total (intervention) | Events/total (placebo) | Drugs (intervention) | Drugs (control) | Lost visits | Percent of lost visits | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Borghi et al. [20] | 1993 | Recurrent calcium stones |
I: 18/7 C: 20/5 |
I: 46.5 C: 42.8 |
40 | 3/19 | 9/21 | Indapamide | No treatment | 10 | 20% | 36 |
| Brocks et al. [10] | 1981 | Recurrent calcium stones | NR | 16–49 | 62 | 5/33 | 5/29 | Bendroflumethiazide | Placebo | 0 | 0 | 48 |
| Ettinger et al. [19] | 1988 | Recurrent calcium stones | NR |
T: L 49.8, H 49.3 C: 48.9 |
73 | 6/42 | 14/31 | Chlorthalidone | Placebo | NR | NR | 36 |
| Fernández-Rodríguez et al. [18] | 2006 | Recurrent calcium stones | NR | NR | 100 | 16/50 | 28/50 | Hydrochlorothiazide | No treatment | 0 | 0 | 36 |
| Laerum et al. [17] | 1984 | Recurrent calcium stones | 38/12 |
T: 45.8 C: 42.7 |
48 | 5/23 | 12/25 | Hydrochlorothiazide + KCl | Placebo | 2 | 4% | 12–51 |
| Mortensen et al. [16] | 1986 | Recurrent kidney stones | All male | 20–49 | 22 | 0/12 | 4/10 | Bendroflumethiazide + KCl | Placebo | 5 | 18.5% | 72 |
| Ohkawa et al. [15] | 1992 | Calcium stones with hypercalciuria |
I: 45/37 C: 52/41 |
I: 48.7 C: 46.9 |
175 | 11/82 | 41/93 | Trichlormethiazide | No treatment | 35 | 16.7% | 6–68 |
| Scholz et al. [9] | 1982 | Recurrent calcium calculi |
I: 14/11 C: 17/9 |
I: 46 C: 41 |
51 | 6/25 | 6/26 | Hydrochlorothiazide | Placebo | 3 | 5.6% | 12 |
I intervention group, C control group, NR not reported, L low dose group, H high dose group, KCl potassium chloride